Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment
JCI - An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Computational Analysis of the Binding Specificity of Gleevec to Abl, c-Kit, Lck, and c-Src Tyrosine Kinases | Journal of the American Chemical Society
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27KIP1 as a consequence of c-Abl inhibition - ScienceDirect
Cancer drug gets a makeover | News | Chemistry World
Diapositiva 1
c-KIT and PDGFRA mutation detection for GIST – آزمایشگاه پرتولب
Imatinib - Wikipedia
Chemical structure of imatinib and its binding modes to c-Kit and Abl.... | Download Scientific Diagram
Discovery of Conformational Control Inhibitors Switching off the Activated c -KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants | Journal of Medicinal Chemistry
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors - ScienceDirect
A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors - Kim - 2022 - Molecular Oncology - Wiley Online Library
c-キッ阻害 | c-Kit Inhibition
![PDF] c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1a2caa75b0240b9cad38286da89c68152befd2d7/11-Figure9-1.png "PDF] c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. | Semantic Scholar")
PDF] c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. | Semantic Scholar
Frontiers | Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
Cancers | Free Full-Text | Resistance to Molecularly Targeted Therapies in Melanoma
Visualisation of the action of imatinib at the KIT receptor | Download Scientific Diagram
Traces of cKIT model and imatinib binding. A, model of the inactive... | Download Scientific Diagram
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours | British Journal of Cancer
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Role and significance of c-KIT receptor tyrosine kinase in cancer: A review | Biomolecules and Biomedicine
For How Long Should Adjuvant Therapy for Gastrointestinal Stromal Tumors (GIST) Be Administered?
